Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Burkitt Lymphoma 2Recurrence 1

Interventions

Specimen Handling 613pembrolizumab 583Magnetic Resonance Spectroscopy 543Carboplatin 430Cyclophosphamide 380Cisplatin 377Biopsy 366Paclitaxel 314Nivolumab 312Gemcitabine 308Radiotherapy 268Bevacizumab 230Dexamethasone 217fludarabine 205Docetaxel 190durvalumab 188venetoclax 187Oxaliplatin 187Rituximab 174Fluorouracil 174atezolizumab 169Pemetrexed 166Capecitabine 162Radiosurgery 160Doxorubicin 160Radiation 156Ipilimumab 144Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × CVAD protocol × 90 days × Clear all
NCT07564453 2026-05-04

FLOW

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
101 enrolled
Lymphoid

Burkitt Lymphoma

NCT06287229 2026-04-24

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence

NCT05581030 2026-03-06

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Recruiting
7 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07223190 2026-03-04

AUDAX

Amgen

Phase 3 Not yet recruiting
560 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡